S21--For Your Consideration: A Debate on De-escalating Therapies?

Friday, October 24, 2025

2:30 PM - 4:30 PM PDT

Location:427-429

Chair(s)

Melissa Richmond, MPT

Provincial Health Services Authority
Dabney Eidson, RRT-NPS

Wellstar MCG Health Children's Hospital of Georgia

This session will examine three foundational pillars of cystic fibrosis therapies: airway clearance, inhaled mucolytics and inhaled antibiotics for chronic pseudomonas. In the style of a pro/con debate, a panel of experts will debate the ‘pro’ and ‘con’ side of de-escalating these chronic therapies in the era of highly effective modulators.

Learning Objectives:

To examine the evidence for and against the de-escalation of inhaled mucolytic therapies. .
To examine the evidence for and against the de-escalation of chronic pseudomonas treatment.
To examine the evidence for and against the de-escalation of airway clearance.

Presentations:

2:30 PM - 4:30 PM PDT

Pro Argument: De-Escalation of Airway Clearance
Speaker: Maggie McIlwaine, PhD – Private Practice
2:30 PM - 4:30 PM PDT

S21.2- Con Argument: De-Escalation of Airway Clearance
Speaker: Brenda M. Button, PhD – Monash University
2:30 PM - 4:30 PM PDT

S21.3- Pro Argument: De-Escalation of Mucolytics
Speaker: Alex Gifford – UH Cleveland Medical Center
2:30 PM - 4:30 PM PDT

S21.4- Con Argument: De-Escalation of Mucolytics
Speaker: Scott H. Donaldson, MD – University of North Carolina at Chapel Hill
2:30 PM - 4:30 PM PDT

S21.5- Pro Argument: De-Escalation of Anti-Pseudomonals
Speaker: Margaret Oates, Pharm.D, BCPPS – Wellstar MCG- Children's Hospital of Georgia
2:30 PM - 4:30 PM PDT

S21.6- Con Argument: De-Escalation of Anti-Pseudomonals
Speaker: Hilary M. Vogt, PharmD, BCPPS – Riley Hospital for Children at Indiana University Health